Requiring coverage for certain pediatric autoimmune neuropsychiatric disorders
Summary
Senate Bill 71 would require coverage, under several West Virginia public and private health coverage laws, for intravenous immunoglobulin (IVIG) therapy used to treat pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), pediatric acute-onset neuropsychiatric syndrome (PANS), and other autoimmune encephalopathies. The bill adds new sections to the PEIA statute, Medicaid statute, and multiple chapters of the insurance code so that these conditions are addressed across state-regulated health plans.
The coverage mandate is not unconditional. For plans issued or renewed after the bill’s effective dates, IVIG therapy would only be covered if the treating physician obtains prior authorization and demonstrates that all other treatments have been exhausted. The bill sets different applicability dates for different programs and markets, including January 1, 2027 for Medicaid and most insurance provisions, and July 1, 2027 for PEIA.
Impact
SB71 would amend state law to create a specific coverage requirement for PANDAS/PANS-related IVIG treatment in PEIA, Medicaid, accident and sickness insurance, group insurance, hospital and medical service corporations, health care corporations, and HMOs. It would place these conditions into multiple sections of the West Virginia Code, thereby requiring affected insurers and public programs to evaluate and potentially cover this therapy when prior authorization and medical necessity criteria are met. The practical effect is to expand access to a specialized treatment while also preserving utilization controls through prior authorization and exhaustion-of-other-treatments requirements.
Sentiment
The bill’s stated purpose and structure suggest generally supportive intent toward families seeking treatment for these pediatric neuropsychiatric conditions, because it would create an explicit coverage pathway rather than leaving coverage uncertain. No committee transcripts or recorded votes were provided, so there is no direct evidence of debate, amendments, or formal support/opposition in the available record. Based on the text alone, the bill appears designed as a patient-access measure with built-in insurer safeguards.
Contention
The main point of contention is likely to be the medical and insurance-policy question of whether IVIG for PANDAS/PANS should be mandated coverage and under what evidentiary standard. Supporters would likely emphasize access to treatment for children with serious neuropsychiatric symptoms, while opponents or cautious stakeholders may focus on the requirement that physicians show all other treatments have been exhausted, the need for prior authorization, and the cost and clinical-evidence concerns associated with mandating coverage for a specialized therapy. Because no discussion transcripts are available, no specific legislator, agency, insurer, or advocacy group positions can be identified from the record.